Redbook 2000: IV.B.3 Pathology Considerations in Toxicity StudiesToxicologic...Dmitri Popov
Redbook 2000: IV.B.3 Pathology Considerations in Toxicity StudiesToxicological Principles for the Safety Assessment of Food IngredientsRedbook 2000Chapter IV.B.3. Pathology Considerations in Toxicity Studies.
This presentation was provided by Leslie McIntosh of Ripeta, during the NISO hot topic event "Preprints." The virtual conference was held on April 21, 2021.
Redbook 2000: IV.B.3 Pathology Considerations in Toxicity StudiesToxicologic...Dmitri Popov
Redbook 2000: IV.B.3 Pathology Considerations in Toxicity StudiesToxicological Principles for the Safety Assessment of Food IngredientsRedbook 2000Chapter IV.B.3. Pathology Considerations in Toxicity Studies.
This presentation was provided by Leslie McIntosh of Ripeta, during the NISO hot topic event "Preprints." The virtual conference was held on April 21, 2021.
This presentation was provided by Alberto Pepe of Authorea, during the NISO hot topic event "Preprints." The virtual conference was held on April 21, 2021.
Toward a reliable and interoperable public repository for natural product-dru...Richard Boyce, PhD
A poster presented at the 2017 Annual Symposium of the American Medical Informatics Association (AMIA 2017). November 04- 08, 2017. Washington, DC. USA
NIH Drug Discovery and Development - NCTT and CTSAsCTSI at UCSF
Presented at the UC Braid Retreat: Imagine a statewide research engine of pooled resources, data, and expertise that accelerates the “translation” of academic research to direct patient benefit. That's the goal of the University of California Biomedical Research Acceleration, Integration, and Development (UC BRAID) program.
Jean-Jacques Degroof, PhD, is an accomplished financial industry executive and academic professional who engages in venture investment. Outside his work, Jean-Jacques Degroof supports the Massachusetts Institute of Technology (MIT) as a member of visiting committees and advisory boards. Moreover, he advances entrepreneurship and innovation at the school by sponsoring activities such as Hacking Arts, the 15K Creative Arts Competition, and an accelerator program.
Since its founding in 1861, MIT has advanced knowledge in the fields of technology, science, and other areas of scholarship. The institution, which was originally founded to drive the United State’s industrial revolution, currently instructs over 11,500 students and and has a research budget of $773,901 million in 2019..
Recently, an MIT chemistry team led by associate professor Brad Pentelute began testing a drug candidate that held promise as a treatment for COVID-19. The drug, a peptide or short protein fragment, mimics proteins found on the surface of human cells. Initial research of the drug has shown it can disarm coronaviruses by binding to a viral protein that the virus uses to enter cells.
For additional information on the study, which was initially reported on the online preprint server bioRxiv, visit http://news.mit.edu/2020/peptide-drug-block-covid-19-cells-0327.
Developing a national strategy to bring pathogen genomics into practiceExternalEvents
http://www.fao.org/about/meetings/wgs-on-food-safety-management/en/
Developing a national strategy to bring pathogen genomics into practice. Presentation from the Technical Meeting on the impact of Whole Genome Sequencing (WGS) on food safety management and GMI-9, 23-25 May 2016, Rome, Italy.
Pine.Bio slide deck - Idea Village CAPITALx (New Orleans Entrepreneur Week 2017)Elia Brodsky
Pine.Bio is changing the clinical bioinformatics speace by applying it's unique biAssociation engine to identify meaningful links between omics and clinical data, empowering better decisions and providing more options to patients.
In silico Drug Design: Prospective for Drug Lead Discoveryinventionjournals
International Journal of Engineering and Science Invention (IJESI) is an international journal intended for professionals and researchers in all fields of computer science and electronics. IJESI publishes research articles and reviews within the whole field Engineering Science and Technology, new teaching methods, assessment, validation and the impact of new technologies and it will continue to provide information on the latest trends and developments in this ever-expanding subject. The publications of papers are selected through double peer reviewed to ensure originality, relevance, and readability. The articles published in our journal can be accessed online.
Neglected infectious diseases such as tuberculosis (TB) and malaria kill millions of people annually and the oral drugs used are subject to resistance requiring the urgent development of new therapeutics. Several groups, including pharmaceutical companies, have made large sets of antimalarial screening hit compounds and the associated bioassay data available for the community to learn from and potentially optimize. We have examined both intrinsic and predicted molecular properties across these datasets and compared them with large libraries of compounds screened against Mycobacterium tuberculosis in order to identify any obvious patterns, trends or relationships. One set of antimalarial hits provided by GlaxoSmithKline appears less optimal for lead optimization compared with two other sets of screening hits we examined. Active compounds against both diseases were identified to have larger molecular weight ([similar]350–400) and logP values of [similar]4.0, values that are, in general, distinct from the less active compounds. The antimalarial hits were also filtered with computational rules to identify potentially undesirable substructures. We were surprised that approximately 75–85% of these compounds failed one of the sets of filters that we applied during this work. The level of filter failure was much higher than for FDA approved drugs or a subset of antimalarial drugs. Both antimalarial and antituberculosis drug discovery should likely use simple available approaches to ensure that the hits derived from large scale screening are worth optimizing and do not clearly represent reactive compounds with a higher probability of toxicity in vivo.
This presentation was provided by Alberto Pepe of Authorea, during the NISO hot topic event "Preprints." The virtual conference was held on April 21, 2021.
Toward a reliable and interoperable public repository for natural product-dru...Richard Boyce, PhD
A poster presented at the 2017 Annual Symposium of the American Medical Informatics Association (AMIA 2017). November 04- 08, 2017. Washington, DC. USA
NIH Drug Discovery and Development - NCTT and CTSAsCTSI at UCSF
Presented at the UC Braid Retreat: Imagine a statewide research engine of pooled resources, data, and expertise that accelerates the “translation” of academic research to direct patient benefit. That's the goal of the University of California Biomedical Research Acceleration, Integration, and Development (UC BRAID) program.
Jean-Jacques Degroof, PhD, is an accomplished financial industry executive and academic professional who engages in venture investment. Outside his work, Jean-Jacques Degroof supports the Massachusetts Institute of Technology (MIT) as a member of visiting committees and advisory boards. Moreover, he advances entrepreneurship and innovation at the school by sponsoring activities such as Hacking Arts, the 15K Creative Arts Competition, and an accelerator program.
Since its founding in 1861, MIT has advanced knowledge in the fields of technology, science, and other areas of scholarship. The institution, which was originally founded to drive the United State’s industrial revolution, currently instructs over 11,500 students and and has a research budget of $773,901 million in 2019..
Recently, an MIT chemistry team led by associate professor Brad Pentelute began testing a drug candidate that held promise as a treatment for COVID-19. The drug, a peptide or short protein fragment, mimics proteins found on the surface of human cells. Initial research of the drug has shown it can disarm coronaviruses by binding to a viral protein that the virus uses to enter cells.
For additional information on the study, which was initially reported on the online preprint server bioRxiv, visit http://news.mit.edu/2020/peptide-drug-block-covid-19-cells-0327.
Developing a national strategy to bring pathogen genomics into practiceExternalEvents
http://www.fao.org/about/meetings/wgs-on-food-safety-management/en/
Developing a national strategy to bring pathogen genomics into practice. Presentation from the Technical Meeting on the impact of Whole Genome Sequencing (WGS) on food safety management and GMI-9, 23-25 May 2016, Rome, Italy.
Pine.Bio slide deck - Idea Village CAPITALx (New Orleans Entrepreneur Week 2017)Elia Brodsky
Pine.Bio is changing the clinical bioinformatics speace by applying it's unique biAssociation engine to identify meaningful links between omics and clinical data, empowering better decisions and providing more options to patients.
In silico Drug Design: Prospective for Drug Lead Discoveryinventionjournals
International Journal of Engineering and Science Invention (IJESI) is an international journal intended for professionals and researchers in all fields of computer science and electronics. IJESI publishes research articles and reviews within the whole field Engineering Science and Technology, new teaching methods, assessment, validation and the impact of new technologies and it will continue to provide information on the latest trends and developments in this ever-expanding subject. The publications of papers are selected through double peer reviewed to ensure originality, relevance, and readability. The articles published in our journal can be accessed online.
Neglected infectious diseases such as tuberculosis (TB) and malaria kill millions of people annually and the oral drugs used are subject to resistance requiring the urgent development of new therapeutics. Several groups, including pharmaceutical companies, have made large sets of antimalarial screening hit compounds and the associated bioassay data available for the community to learn from and potentially optimize. We have examined both intrinsic and predicted molecular properties across these datasets and compared them with large libraries of compounds screened against Mycobacterium tuberculosis in order to identify any obvious patterns, trends or relationships. One set of antimalarial hits provided by GlaxoSmithKline appears less optimal for lead optimization compared with two other sets of screening hits we examined. Active compounds against both diseases were identified to have larger molecular weight ([similar]350–400) and logP values of [similar]4.0, values that are, in general, distinct from the less active compounds. The antimalarial hits were also filtered with computational rules to identify potentially undesirable substructures. We were surprised that approximately 75–85% of these compounds failed one of the sets of filters that we applied during this work. The level of filter failure was much higher than for FDA approved drugs or a subset of antimalarial drugs. Both antimalarial and antituberculosis drug discovery should likely use simple available approaches to ensure that the hits derived from large scale screening are worth optimizing and do not clearly represent reactive compounds with a higher probability of toxicity in vivo.
INTRODUCTION
A PERFECT THERAPEUTIC DRUG
DRUG DISCOVERY- HISTORY
MODERN DRUG DISCOVERY
BIOINFORATICS IN DRUG DISCOVERY
DRUG DISCOVERY BASED ON BIOINFORMATIC TOOLS
BIOINFORMATICS IN COMPUTER-AIDED DRUG DISCOVERY
ECONOMICS OF DRUG DISCOVERY
CONCLUSION
REFERENCES
We have 13 research and development projects within:
• Research
• Oncology
• Respiratory, Inflammation and Autoimmunity
• Cardiovascular and Metabolic Disease
• Antibody Discovery and Protein Engineering
• Pathology
• Biopharmaceutical Development
• Cell Culture and Fermentation Sciences
• Formulation Sciences
• Analytical Biotechnology Science
Exploiting drug targets for Immuno-Oncology drug discoveryVikram Rao
IO innovators are increasingly pursuing the CD molecules as targets for new therapies, for example in developing antibodies for immune modulation and cytotoxicity.
This requires a deep understanding of the gene’s role in cancer biology.
Find out how we can help you with understanding the relationship between CD genes and checkpoint inhibitors... exploring different approaches to patient response biomarkers, and prioritise novel drug targets.
Global Medical Cures™ | PCAST Report- Combating Antibiotic ResistanceGlobal Medical Cures™
Global Medical Cures™ | PCAST Report- Combating Antibiotic Resistance
DISCLAIMER-
Global Medical Cures™ does not offer any medical advice, diagnosis, treatment or recommendations. Only your healthcare provider/physician can offer you information and recommendations for you to decide about your healthcare choices.
Global Medical Cures™ | PCAST Report- Combating Antibiotic Resistance
CETR - Rutgers NJ Medical School
1. Rutgers New Jersey Medical School
http://njms.rutgers.edu/research/cetr/index.cfm[11/28/2015 6:04:36 PM]
Overview
An epidemic of multidrug-resistant (MDR) bacetrial infections plagues global and U.S. healthcare, and with few new
antibiotics making it to market from a diminished pipeline, there is an unmet medical need for new therapeutics to treat
drug-resistant infections. Furthermore, effective therapies are urgently needed to address ongoing public health and
biosecurity concerns that high-threat select agent bacetria can be engineered to become resistant to currently available
antibiotics. The goal of the Rutgers CETR is to help develop a new generation of antibiotics against known MDR
bacetria. The CETR is a collaborative public-private partnership involving senior investigators at Rutgers University,
Rockefeller University and Cubist Pharmaceuticals. It will serve to jump-start the discovery of novel antibiotics by
joining together highly creative senior researchers and providing critical core resources to turn highly promising early
concept molecules into potential therapeutics suitable for clinical evaluation. The CETR will examine well established
and novel therapeutic targets, and it will facilitate target validation, chemical lead identification, structure-activity
relationship analysis, pharmacokinetics and therapeutic efficacy in animal models. The goal is to develop optimized
chemical lead compounds that are suitable antibiotic candidates for preclinical evaluation. Critical factors for success
include the strength of highly accomplished project and core leaders, a comprehensive and highly integrated
infrastructure of support cores for lead compound optimization and validation, and access to the Rutgers Regional
Biocontainment Laboratory (RBL), an NIH designated national research center for high-threat agents. Finally, the
CETR leadership group is highly experienced in executing product-oriented translational research and a Scientific
Advisory Committee comprised of veteran members of PhRMA and academia will guide them.
Projects
Project 1: Therapeutics for drug resistant-bacetria: Arylpropionyl-phloroglucinods
2. Rutgers New Jersey Medical School
http://njms.rutgers.edu/research/cetr/index.cfm[11/28/2015 6:04:36 PM]
PI: Richard Ebright, Rutgers, the State University of NJ
Project 2: Broad spectrum Tricyclics GyrB, ParE inhibitors for antibacetrial application
PI: Aileen Rubio, Cubist Pharmaceuticals
Project 3: Process and pathway based discovery of novel anti-TB drugs
PI: David Alland, Rutgers, the State University of NJ
Project 4: Synthetic environmental-peptide libraries as a source of novel antibiotics
PI: Sean Brady, Rockefeller University
Project 5: Bayesian models to accelerate antibacetrial drug discovery
PI: Joel Freundlich, Rutgers, the State University of NJ
Cores
Core A: Administrative
PI: David Perlin, Rutgers, the State University of NJ
Core B: In vivo and in vitro pharmacokinetics
PI: Veronique Dartois, Rutgers, the State University of NJ
Core C: Animal Model
PI: David Perlin, Rutgers, the State University of NJ
Core D: Medicinal Chemistry
PI: Joel Freundlich, Rutgers, the State University of NJ
Core E: Structural refinement
PI: Min Lu, Rutgers, the State University of NJ
Core F: In vitro screening
PI: Nancy Connell, Rutgers, the State University of NJ